About the Report
High content screening (HCS) is also known as cellomics. It is a method used in drug discovery and biological research to discover new drug candidates. High content screening systems is primarily based on digital microscopy and flow cytometry with the combination of IT systems for the storage and analysis of biological data. High content screening techniques have proven to be very useful for the pharmaceutical industry for the characterization of preclinical drugs.
This technology is often combined with various other applications such as drug development. The combination of HCS with chemical genetics for the study of biologicals systems is set to pave way for increasing uptake in the coming years. Moreover, the technology has unified all the aspects of drug discovery, toxicity and evaluation of absorption, distribution, metabolism, and excretion. Besides this, increasing biotechnology research and drug development activities create huge opportunities for growth.
In its new study, the consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for high content screening. The report tracks the global sales of high content screening systems in 20+ high-growth markets, along with analyzing the impact of COVID-19 on the healthcare industry in general, and high content screening in particular.
The COVID-19 pandemic impacted adversely on the research and drug development process in 2020. Due to the continuous lock down and shut down by the government all over the world hampered the ongoing research activities. Prior to COVID-19 pandemic high content screening equipment’s were largely preferred by the emerging countries for cell imaging and toxicity studies. However, due to the pandemic, the high content screening market suffered a lot with delay in product launches, and noticeable reduction of sales of major products.
How Historical and Future Outlook for High Content Screening Market Match Up?
Growing focus on secondary screening of cells by the leading market players due to the high focus on drug toxicity studies has led to a surge in demand for high content screening in recent years. Increasing pharmaceutical and biotechnology companies with a continuous focus on novel drug development have also created opportunities for the development of technological advance high content screening systems.
For instance, in September 2017, the company Yokogawa launched its cellVoyager CV8000, a Cytological High-throughput Discovery System for the discovery of new drugs in a time saving and improved efficiency.
According to FMI’s analysis, high-content-screening sales have grown at about 6% CAGR between 2016 and 2031. Advancement in cell imaging technology with continuous research and development activities towards the innovation and discovery of novel drugs are the factors responsible for the growth of high content screening during the forecast period.
Furthermore, the increasing incidence of several infectious diseases with diverse symptoms also increases the demand for novel therapeutics. Consequently, increase in the biotechnology and pharmaceutical research and development activities to find out new drug candidates. Imaging technologies playing a huge role in drug discovery and research.
The leading manufacturers in the market are looking forward to developing technologically advance and cost-effective high content screening systems to meet the global demand, hence expected to accelerate the market growth over the forecast years. Emerging countries such as China, India with the rise in biotechnology research and drug development activities also offer huge opportunities for the key manufacturers. These factors present a positive growth outlook. FMI expects the global high content screening market to grow over 5.9% CAGR through 2031.
What are the Key Factors Fuelling Demand for High Content Screening?
Increasing cases of neurodegenerative life-threatening diseases such as cancer, spinal muscular atrophy, Alzheimer, and Parkinson's across the globe is expected to drive demand for advances healthcare services. This has led international players across the globe to invest considerably in research and development to launch innovative products and to cater the demand across the supply chain shortly.
For instance, according to the World Health Organization (WHO) globally the number of deaths from cancer will continue to rise and reach around 13.1 billion by 2031. It also suggests that global prevalence of cancer will be increase around 75% from 2008 to 2031. Increasing growth of the cancer all over the globe will lead to an increased number of patients who will undergo cancer management and treatment. This in turn would increase the demand for more number of novel biologics thereby driving the growth of the high content screening market.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Will Investments In Drug Discovery Create Growth Prospects?
Growing investments in biological research and drug discovery by government and non-government organizations to identify substances, such as peptides, small molecules, and RNAi is expected to boost the high content screening market growth. Conventional methods used for toxicity studies and drug discovery have a low success rate and time-consuming. Advanced high content cell imaging technology with integrated IT solution provides a better result in in-vitro toxicity testing in reduced time.
Large scale investment in drug discovery by government organizations around the globe is fuelling the demand for advanced high content screening systems. The growing trend of secondary screening of cells in recent years also is expected to propel growth over forecast years. Furthermore, risk assessment of critical diseases is gaining importance for drug discovery across pharmaceutical and biotechnology companies. Thus, the development of solutions, which offer high sensitivity in detecting problems as critical as hepatoxicity is expected to drive the demand for high content screening instruments.
How Demand For Multiplex Information Propels Market Growth?
The importance of multiplex information in drug discovery is accelerating the demand for high content screening instruments. These instruments generate and provide live-cell imaging information to identify new drug targets. The information generates from multiplex screening using high content screening instruments provides data of multiple nodes in a cellular pathway. Growing preference for cell imaging in complex cellular systems to identify new drug targets also expected to boost high content screening market growth.
Growing demand for multiplexed high content screening assays in drug discovery to identify multiple drug targets creates a huge opportunity for the manufacturers to develop advanced high content screening instruments. Advancement of IT integrated high content screening systems generates and stores multiplex cellular information with deeper functional knowledge, thereby improving the early drug discovery process. Moreover, increasing demand for multiplex information in the drug discovery process is expected to drive high content screening market growth in the upcoming years.
How is New Product Developments Affecting Growth?
High content screening equipment is increasingly used for primary & secondary screening of drug molecules, target identification & validation, toxicity studies and compound profiling. A growing number of pharmaceutical, biotechnology and educational institutions across the globe creating huge opportunities for manufacturers to develop technological advance high content screening equipment. Manufacturers in the global high content screening market now focusing to introduce new technological advance high content screening systems to enhance their efficacy and reliability.
For instance, in October 2020 CytoSMART Technologies announced to launch a new advance automated live cell imaging system designed for long-term experiments, large laboratory studies, and comparison studies.
How is Manufacturing Facility Expansion Driving HCS Market?
Some of the leading manufacturers are expanding their presence in emerging and untapped regions to maintain or gain market share in the global market. Substantial investments in the manufacturing facility expansion of high content screening systems manufacturing are one of the major trends among key players in the global market.
The leading players in the market are looking forward to holding a strong position in the international market by opening up new product manufacturing facilities.
For instance, in September 2019, Siemens Healthlineers opened up a new medical imaging manufacturing facility in Bengaluru, India and strengthening its market presence in this region.
How big is the Opportunity in the U.S?
According to FMI, the U.S will remain one of the leading markets for the high content screening t. The presence of leading market players in the region and increasing adoption of advance imaging technology are the major factors creating opportunities for growth in the content screening market in the U.S.
Besides this, one of the key factors supporting the growth, is the U.S’s high spending on healthcare. As per the forecasts by CMS’ Office of the Actuary, the overall healthcare spending is faster increased about 4.6% in 2019 than the overall economic growth of 4.0% in the United States measured by Gross Domestic Product (GDP) in 2019.
Furthermore, high per capita healthcare spending and favourable healthcare policies have created a conducive environment for the adoption of advanced cell imaging instruments in the U.S. Also the presence of leading players such as Becton, Dickinson and Company, Thermo Fisher Scientific, and GE Healthcare is supporting growth in the U.S. Moreover, the key business strategies followed by these companies such as product launches and expansion plans will continue aiding the overall expansion of the market in the U.S.
What are the Factors Shaping the Germany HCS Market?
The increasing number of biotech and pharmaceutical companies is expected to accelerate the high content screening instruments sale in the German market. Further, increasing funding for biotechnology research and drug development also accelerates the growth of the high content screening market in Germany.
FMI forecasts Germany as the leading market for sales within Europe. With rising numbers of strong and internationally recognized biotechnology institutions, Germany holds a high position in drug development activities in Europe. Germany has around 220 biotech and pharmaceutical companies working on new drug candidates.
Novel business model, coupled with network management between universities and government research associations such as Leibniz Association, Helmholtz, Max Planck and the Fraunhofer Society in Germany for drug development, is creating demand for the high content screening in the region.
How Increasing Drug Discovery and Development Activities in China Driving HCS Uptake?
China has a good foundation in drug discovery and development. Presently there is above 5,000 pharmaceutical companies operating in China. The government of China is also supported by investing in pharma and drug discovery in order to make China a major market in innovative drug discovery and development. As high content screening equipment has direct application in cell toxicity, cell imaging, primary & secondary screening, target identification & validation, manufacturers are looking for large scale investment in china to expand their business in this region.
China is the largest market for drug development and innovation in Asia. The country accounts for about 19% of the world's population and over 22% of people over 65 age. Aging people are prone to diseases and various health conditions. It is necessary for the country to discover and develop novel drug candidate which now turns in to an ambition. Further, China’s biotech industry is booming, exhibiting impressive growth. China accounts for about 7.8% of the global drug innovation pipeline and 11.6% of new drug launches in 2018.
How are Favorable Policies Impacting India High Content Screening Market?
The government in India has been funding several programs to boost pharmaceutical and biotechnology industry, which is anticipated to propel the high content screening market growth during forecast years. The government of India launched the national biotechnology development strategy (2015-2020) to create an ecosystem and R&D infrastructure for the development of biotech products.
About 30 biotech parks were started between April 2014 and September 2016 by the government. Further, India is also considered one of the top 12 destinations for biotechnology research in the world which is expected to fuel the demand for the adoption of high content screening equipment's in this region.
What’s the Market Share of Cell Imaging & Analysis?
Wider preference of high content screening for cell imaging & analysis is anticipated to drive the market over the forecast years. The use of high content screening equipment in the exploration and development of new drugs through cell imaging & analysis also provides a high market value share to the segment.
In the target identification & validation process high content screening equipment’s plays a major role for cell imaging which is also anticipated to provide considerable impetus to the cell imaging & analysis segment in terms of product type.
Cellular imaging & analysis is performed to measure and evaluate the current state of cells, such as cell toxicity, integrity, and viability for the drug development. For such analysis of cell high content screening equipment’s are increasingly used which is the major factor behind the high revenue share of the segment.
Why is Pharmaceutical & Healthcare Considered Leading End User?
Pharmaceutical and healthcare institutes are actively involved in drug discovery and development activities around the globe. A gradual increase in pharmaceutical & healthcare institutions is expected to increase its revenue share in the industry segment. Growing economy, coupled with increasing healthcare expenditure, creates a huge demand for opening up new healthcare and pharmaceutical institutes. High content screening is used to analyze whole cells or components of cells to the development of drug candidate.
Pharmaceutical companies are involved in various drug development processes such as primary screening, toxicology testing, and secondary screening, using advance equipment like high content screening. High content screening is widely being accepted by several emerging pharma companies involved in the drug development process.
Increasing adoption due to high accuracy, time-saving and reliability of high content screening equipment’s than traditional cell imaging equipment's, by the pharma and healthcare institutions is responsible for a high revenue share of the segment in the global high content screening market.
High content screening finds application in primary and secondary screening across various industries. This is expected to continue fuelling the demand through the course of the forecast period.
Manufacturers in the high content screening market are aiming at strategic acquisition of medium and small manufacturers to expand their product manufacturing and address the demand for expanding patient pool. For instance, in 2017, Sysmex Corporation acquired Oxford Gene Technology (OGT). The company used to conduct business in the area of cytogenic testing, which involved testing cells for chromosomal and genetic abnormalities. In August 2017, Thermo Fisher Scientific Inc. acquired Pantheon N.V, a Leading contract development and manufacturing organization that was serving the pharmaceutical and biotechnology sector.
Manufacturers are also focusing on the expansion of the product portfolio by launching new technological advance products. For instance, in June 2020, Olympus launched a new cell imaging system SciLog SciPure FD System, to capture high-quality multicolour images quickly and with better quantitative results.
Some of the leading companies operating in the market are:
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- GE Healthcare
- Olympus Corporation
- PerkinElmer Inc.
- Sysmex Corporation
- Merck KGaA
- Danaher Corporation
- Yokogawa Electric Corporation
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Scope of the Report
Historical Data Available for
USD Million for value and Units for Volume
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa
Key Countries Covered
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa
Key Segments Covered
Component, Application, End-User, and Region
Key Companies Profiled
Market Forecast, Company share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Key Questions Answered in the Report
Which is the most lucrative market for the high content screening?
The U.S. currently leads the global market for high-content-screening (HCS). Sales in the U.S. will be account for over 91% of sales recorded in the North America throughout the forecast period.
Which is the top-selling high content screening equipment?
High content screening equipment and flow cytometers used for cell imaging and analysis are the top-selling instruments in the HCS market.
For which application is high content screening primarily used?
High content screening is primarily used for primary & secondary screening of new drug molecules. Increasing new drug candidate exploration is likely to accelerate the adoption of high content screening equipment for primary & secondary screening.
Which are some of the leading companies offering High-Content-Screening?
Some of the leading companies offering high content screening are Thermo Fisher Scientific Inc., Danaher Corporation, Merck Millipore (Merck Group), Becton, Dickinson and Company and Olympus Corporation, among others.
Enquiry Before Buying
- Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to a research analyst
- What research methodology is followed by FMI?
FMI follows a methodology that encompasses the demand-side assessment of the market and triangulates the same through supply-side analysis. This methodology is based on the use of standard market structure, methods and definitions. Request detailed methodology
- Who are the respondents for primary research?
FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.
- What are the sources of secondary research?
FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
- Is a sample of this report available for evaluation?
Yes, you can request a sample and it will be sent to you through an email.
- How can I buy this report?
FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.
High-Content-Screening Market by Category
- Cell Imaging & Analysis
- HCS Instruments
- High-End HCS
- Mid End HCS
- Low-End HCS
- Flow Cytometers
- HCS Instruments
- Reagents & Assay Kits
- Other Consumables
- Pharmaceutical & Healthcare
- Educational Institutions
- Independent CRO
- Government Organizations
- Primary & Secondary Screening
- Target Identification & Validation
- Toxicity Studies
- Compound Profiling
- North America
- Latin America
- East Asia
- South Asia
- Middle East and Africa (MEA)